Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo-Controlled Observation in the ODYSSEY OUTCOMES Trial.
Goodman SG, Steg PG, Poulouin Y, Bhatt DL, Bittner VA, Diaz R, Garon G, Harrington RA, Jukema JW, Manvelian G, Stipek W, Szarek M, White HD, Schwartz GG; ODYSSEY OUTCOMES Investigators. Goodman SG, et al. Among authors: garon g. J Am Heart Assoc. 2023 Sep 19;12(18):e029216. doi: 10.1161/JAHA.122.029216. Epub 2023 Sep 13. J Am Heart Assoc. 2023. PMID: 37702079 Free PMC article. Clinical Trial. No abstract available.
Safety Of The Pcsk9 Inhibitor Alirocumab: insights From 47,296 Patient-Years Of Observation.
Goodman SG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Harrington RA, Jukema JW, White HD, Zeiher AM, Manvelian G, Pordy R, Poulouin Y, Stipek W, Garon G, Schwartz GG. Goodman SG, et al. Among authors: garon g. Eur Heart J Cardiovasc Pharmacother. 2024 Apr 24:pvae025. doi: 10.1093/ehjcvp/pvae025. Online ahead of print. Eur Heart J Cardiovasc Pharmacother. 2024. PMID: 38658193
Relating Lipoprotein(a) Concentrations to Cardiovascular Event Risk After Acute Coronary Syndrome: A Comparison of 3 Tests.
Szarek M, Reijnders E, Jukema JW, Bhatt DL, Bittner VA, Diaz R, Fazio S, Garon G, Goodman SG, Harrington RA, Ruhaak LR, Schwertfeger M, Tsimikas S, White HD, Steg PG, Cobbaert C, Schwartz GG; ODYSSEY OUTCOMES Investigators. Szarek M, et al. Among authors: garon g. Circulation. 2024 Jan 16;149(3):192-203. doi: 10.1161/CIRCULATIONAHA.123.066398. Epub 2023 Aug 26. Circulation. 2024. PMID: 37632469 Free PMC article.
Comparison of Change in Lipoprotein(a) Mass and Molar Concentrations by Alirocumab and Risk of Subsequent Cardiovascular Events in ODYSSEY OUTCOMES.
Szarek M, Reijnders E, Steg PG, Jukema JW, Schwertfeger M, Bhatt DL, Bittner VA, Diaz R, Fazio S, Garon G, Goodman SG, Harrington RA, White HD, Zeiher AM, Cobbaert C, Schwartz GG. Szarek M, et al. Among authors: garon g. Eur J Prev Cardiol. 2024 Mar 19:zwae110. doi: 10.1093/eurjpc/zwae110. Online ahead of print. Eur J Prev Cardiol. 2024. PMID: 38501249 No abstract available.
Efficacy and Safety of Single-Pill Combination of Rosuvastatin and Ezetimibe in Chinese Patients with Primary Hypercholesterolemia Inadequately Controlled by Statin Treatment (ROZEL): A Randomized, Double-Blind, Double Dummy, Active-Controlled Phase 3 Clinical Trial.
Su Q, Liu Y, Zhang G, Xu L, Wang M, Mei S, Garon G, Wu Y, Lv Q, Ma C. Su Q, et al. Among authors: garon g. Adv Ther. 2023 Dec;40(12):5285-5299. doi: 10.1007/s12325-023-02666-z. Epub 2023 Sep 28. Adv Ther. 2023. PMID: 37770770 Free PMC article. Clinical Trial.
16 results